Infant formula company, Nuchev Limited, has appointed Nathan Cheong as its new CEO, taking up the role from Mick Myers, who will transition to COO in conjunction with his previous position as CFO.
Myers was appointed interim CEO and CFO on 15 December 2023, after the resignation of Greg Kerr, and subsequently appointed as CEO from 1 July 2024.
“I am excited to have Nathan join us and believe now is the right time to make this transition. I’m looking forward to fast tracking our momentum with the addition of Nathan’s capabilities joining the team,” said Myers.
Cheong has provided his resignation as an independent non-executive director on the Nuchev board, which he has been on since September 2024, and will take over from Myers after a transition period.
“I am delighted to be joining Nuchev as CEO and continuing the great work that Mick and the team have been doing,” said Cheong.
“I am very pleased Mick has agreed to continue with the Group, and work with me over the next phase of Nuchev’s development. The company has built a solid framework to build upon and I see exciting opportunities ahead.”
The Nuchev board stated Cheong is an experienced managing director and CEO, having worked in the medicine industry for over 20 years. He most recently served as CEO of Melrose Group, and has previously worked for companies including Life Space Group, Designs for Health, BioCeuticals and Global Therapeutics.
Chair of the board, Ben Dingle, said: “The board is delighted to secure Nathans’ services as an outstanding CEO and retaining the complimentary skills and corporate knowledge of Mick as CFO/exiting CEO. The board sees this as a natural transition which will enable further momentum in executing our strategy.”
